Telaprevir dosing regimen

A drug and stage technology, applied in the field of telaprevir, can solve the problem of no alternative treatment methods

Inactive Publication Date: 2011-06-01
JANSSEN PHARMA NV +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In many parts of the world, no alternative treatment with proven superiority is currently available for patients who do not achieve SVR following Peg-IFN / RBV therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telaprevir dosing regimen
  • Telaprevir dosing regimen
  • Telaprevir dosing regimen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Randomized, double-blind, placebo-controlled trial of telaprevir in patients with chronic HCV genotype 1 infection refractory to prior therapy with Peg-IFN (Peg-IFN alfa-2a or Peg-IFNalfa-2b) plus RBV Research. The trial was designed to compare the efficacy, safety of two regimens of telaprevir combined with Peg-IFN alfa-2a and RBV (with and without delayed start) versus standard therapy (Peg-IFN alfa-2a and RBV) and tolerance.

[0041] The trial consisted of a screening period of approximately 4 weeks, a treatment period of 48 weeks, and a follow-up period of 24 weeks. figure 1 Displays a graphical overview of the experimental design.

[0042] Patients participating in this study meet any of the following criteria:

[0043] (1) Patients with undetectable HCV RNA levels at the end of a prior course of Peg-IFN / RBV therapy, but who did not achieve SVR (viral relapser), or

[0044] (2) Patients who never had undetectable HCV RNA levels at the end of or during the cours...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.

Description

[0001] The invention relates to the use of telaprevir combined with peg-IFN and ribavirin (RBV) in treating HCV patients. In particular, the use of a specific dosing regimen of telaprevir in combination with peg-IFN and ribavirin. Background of the invention [0002] Hepatitis C is a liver disease caused by the hepatitis C virus, which is found in a patient's blood. HCV, infecting 3.4 million people in the United States, is a serious public health problem that is transmitted through direct contact with the blood of infected individuals. While many people with HCV infection may not have symptoms, others may have symptoms such as jaundice, abdominal pain, fatigue, and fever. The burden of liver disease associated with HCV infection is increasing, and existing treatments typically have a sustained effect in fewer than half of patients with genotype 1 HCV, the most common species of the virus. [0003] Standard therapy for HCV patients consists of a combination of pegylated inte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/497A61K31/7056A61K47/48A61P31/14A61K38/21
CPCA61K31/7056A61K31/497A61K47/48215A61K47/48092A61K38/21A61K2300/00A61K47/60A61K47/549A61P1/16A61P31/14A61P43/00
Inventor M·G·比蒙特S·R·赫蒂纽斯G·R·皮基奥R·波洛R·S·考夫曼B·S·阿迪维贾亚V·加尔格
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap